当前位置:首页 - 行情中心 - 三元生物(301206) - 财务分析 - 利润表

三元生物

(301206)

  

流通市值:35.11亿  总市值:54.53亿
流通股本:1.30亿   总股本:2.02亿

利润表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、营业总收入224,781,048.39649,511,864.38476,077,165.85317,965,979
  营业收入224,781,048.39649,511,864.38476,077,165.85317,965,979
二、营业总成本208,040,014.29615,716,180.92450,764,643.46288,093,382.43
  营业成本187,322,978.08544,823,711.67399,176,492.76256,915,517.33
  税金及附加1,113,492.983,673,146.792,799,751.111,721,037.59
  销售费用2,810,922.548,355,078.226,176,169.394,267,456.32
  管理费用7,359,170.9829,519,901.8323,135,356.5215,294,309.4
  研发费用8,240,074.8134,417,125.9224,800,042.414,794,149.7
  财务费用1,193,374.9-5,072,783.51-5,323,168.72-4,899,087.91
  其中:利息收入1,946,448.936,713,474.495,514,743.713,821,935.81
三、其他经营收益
  加:公允价值变动收益1,945,644.14367,116.65--
  加:投资收益9,953,485.0869,511,758.0251,329,576.1236,233,619.1
  资产处置收益-65,753.1610,577.18-36,368.8
  资产减值损失(新)-138,865.95-272,312.9--
  信用减值损失(新)202,024.25168,848.1572,740.76-164,372.92
  其他收益726,757.421,402,320.541,057,160.99663,002.99
四、营业利润29,430,079.04105,039,167.0877,782,577.4466,568,476.94
  加:营业外收入18,891.6482,257.9680,912.6979,271.34
  减:营业外支出56.0494,336.0494,333.4932,748.86
五、利润总额29,448,914.6105,427,08977,769,156.6466,614,999.42
  减:所得税费用3,357,470.314,130,529.0410,484,491.799,247,149.57
六、净利润26,091,444.391,296,559.9667,284,664.8557,367,849.85
(一)按经营持续性分类
  持续经营净利润26,091,444.391,296,559.9667,284,664.8557,367,849.85
(二)按所有权归属分类
  归属于母公司股东的净利润26,091,444.391,410,640.5967,398,745.4857,481,930.48
  少数股东损益--114,080.63-114,080.63-114,080.63
  扣除非经常损益后的净利润22,862,806.8775,935,866.2857,134,312.5348,756,638.97
七、每股收益
  (一)基本每股收益0.130.460.340.29
  (二)稀释每股收益0.130.460.340.29
八、其他综合收益-160,103.28158,013.72--
  归属于母公司股东的其他综合收益-160,103.28158,013.72--
九、综合收益总额25,931,341.0291,454,573.6867,284,664.8557,367,849.85
  归属于母公司股东的综合收益总额25,931,341.0291,568,654.3167,398,745.4857,481,930.48
  归属于少数股东的综合收益总额--114,080.63-114,080.63-114,080.63
公告日期2026-04-292026-04-292025-10-272025-08-29
审计意见(境内)标准无保留意见
TOP↑